登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C33H34N6O6
化学文摘社编号:
分子量:
610.66
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
产品名称
坎地沙坦酯, European Pharmacopoeia (EP) Reference Standard
InChI
1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38)
SMILES string
CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc4ccc(cc4)-c5ccccc5-c6nnn[nH]6
InChI key
GHOSNRCGJFBJIB-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
candesartan
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Gene Information
human ... AGTR1(185)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
坎地沙坦酯是一种非肽血管紧张素（AT2）受体拮抗剂。
坎地沙坦酯是有效的血管紧张素 II 受体拮抗剂坎地沙坦的前药形式。 该前药在肠道内被酯酶裂解释，并放活性分子。
Application
Candesartan cilexetil for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
signalword
Danger
hcodes
Hazard Classifications
Repr. 1B - STOT RE 2 Oral
target_organs
Kidney,Blood
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
J M Mallion et al.
Journal of human hypertension, 14 Suppl 2, S33-S41 (2000-11-22)
Candesartan is one of the first angiotensin II receptor antagonists (AIIRAs) to be developed. It binds tightly to and dissociates slowly from the angiotensin subtype 1 (AT1) receptor in vitro. These binding characteristics differ from those of losartan, which demonstrates
Ezequiel Balmori Melian et al.
Drugs, 62(5), 787-816 (2002-04-04)
The combination of candesartan cilexetil [an angiotensin II type 1 (AT(1)) receptor antagonist] plus hydrochlorothiazide (a thiazide diuretic), has been used in the treatment of patients with hypertension. The blood pressure (BP) lowering effect of various doses of this combination
Stephanie E Easthope et al.
Drugs, 62(8), 1253-1287 (2002-05-16)
Candesartan cilexetil is converted to the angiotensin II receptor antagonist candesartan during absorption from the gastrointestinal tract. The selective and competitive binding of candesartan to the angiotensin II type 1 (AT(1)) receptor prevents binding of angiotensin II, a key mediator
Sheridan M Hoy et al.
American journal of cardiovascular drugs : drugs, devices, and other interventions, 10(5), 335-342 (2010-09-24)
Candesartan cilexetil is the orally administered prodrug of candesartan, an angiotensin II subtype 1 receptor antagonist. The pharmacokinetics (area under the plasma concentration-time curve and maximum plasma concentration) of candesartan do not appear to be affected by age, sex, or
Caroline Fenton et al.
Drugs, 65(4), 537-558 (2005-03-01)
Candesartan cilexetil is the orally administered pro-drug of candesartan, a highly selective antagonist of the angiotensin II subtype 1 receptor that mediates the pressor activities of angiotensin II. Candesartan cilexetil is widely used for the treatment of hypertension and has
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持